서울특별시내과

제52차 대한암학회 학술대회

Name: 제52차 대한암학회 학술대회
Start: 2026-06-25
End: 2026-06-26
Location: 그랜드인터컨티넨탈 서울 파르나스 2,5층

6점 일반 6

주최: 대한암학회
일자: 2026-06-25 ~ 2026-06-26 (2일)
장소: 그랜드인터컨티넨탈 서울 파르나스 2,5층
수강료: 300,000원 구분별

수강료 구분별 상세보기

1. 회원: 1) 교수,전문의,선임연구원: 15만원 / 2) 전공의,연구원,대학원생: 7만원 / 3) 업체,연구소: 20만원, 2. 비회원: 1) 교수,전문의,선임연구원: 20만원 / 2) 전공의,연구원,대학원생: 7만원 / 3) 업체,연구소: 30만원

원문 기준 · 정확한 등록비는 KMA 신청 페이지에서 확인하세요.

평점 구성

총 평점6점

필수평점0점

일반평점6점

연수평점은 3년 24점·연 8점 상한·필수 2점 요건이 있습니다. 이 행사 들으면 올해 상한까지 몇 점? →

KMA 등록 페이지에서 신청 → 평점 계산기

세부 일정 (109강 · 2일)

날짜를 눌러 해당 일자 프로그램을 펼쳐보세요.

Day 1 2026-06-25 (목) 50강

09:00~09:25 Expansion-assisted 3D multiplexed protein imaging of the brain GBR A 장재범(KAIST)
09:25~09:50 Structural variants drive context-dependent oncogene activation in cancer GBR A 이동성(서울대)
09:50~10:15 Deciphering the immunotherapy response paradox in RCC: Insights from single-cell and spatial transcriptomics GBR A 강민용(성균관의대)
10:15~10:40 AI-based pathology GBR A 노명균(아주의대)
09:00~09:25 Multi-cancer early detection using liquid biopsy GBR B Harpal Kumar(GRAIL, UK)
09:25~09:50 Integrating cfDNA fragmentomics and genomics for early cancer screening GBR B 조은해(녹십자지놈)
09:50~10:15 Beyond blood: Unlocking the diagnostic potential of alternative body fluids in liquid biopsy GBR B 이승태(연세의대)
10:15~10:40 Multimodal liquid biopsy–radiology integration for the noninvasive diagnosis of gallbladder cancer GBR B Yingbin Liu(Shanghai Jiao Tong University, China)
09:00~09:25 Advances in bispecific antibodies and BiTEs: Recent clinical progress GBR C 김혜련(연세의대)
09:25~09:50 Next-generation antibody–drug conjugates: Innovative antibody engineering and linker–payload design GBR C Raffaele Colombo(Zymeworks Inc., Canada)
09:50~10:15 From platform to pipeline: Translational strategies for developing 4-1BB bispecific T-cell engagers and bispecific ADCs GBR C 이상미(ABL Bio)
10:15~10:40 Recent advances in novel ADC and bispecific antibody drug in breast cancer GBR C 이수정(경북의대)
09:00~09:30 Deciphering the impact of environmental factors on epigenetics in cancer: An integrated multi-omics approach Rose 원성호(서울대)
09:30~10:00 Environmental exposure and lung cancer mediated by epigenetic regulation Rose 김우진(강원의대)
10:00~10:30 Transcriptomic and epigenetic reprogramming during tumorigenesis Rose 백인화(경희대 약대)
11:00~11:40 Decoding the drivers of anti-tumor immunity GBR David Braun(Yale School of Medicine, USA)
11:40~12:20 Decoding molecular complexity and cellular senescence in glioblastoma GBR Adelheid Woehrer(Medical University of Innsbruck, Austria)
12:20~12:40 Role of subsequent TKIs in the first-line immunotherapy era in advanced HCC GBR A 유창훈(울산의대)
12:20~13:00 CLDN18.2-targeted therapy as a new standard of care in advanced gastric cancer: Clinical trial evidence and real-world experience with zolbetuximab GBR B 권민석(삼성서울병원)
13:40~14:05 Comprehensive proteomic characterization of human cancers GBR A 이상원(고려대)
14:05~14:30 Clinical proteomics in lung cancer: Navigating new targets beyond the genom GBR A 한지연(국립암센터)
14:30~14:55 Spatiotemporal proteomics for constructing virtual cell models GBR A Tiannan Guo(Westlake University, China)
14:55~15:20 Targeted protein degradation: From mechanism to therapeutic development GBR A 심태보(연세의대)
13:40~14:05 Next generation organoid model for glioblastoma research GBR B 윤기준(KAIST)
14:05~14:30 Next generation precision medicine for cancer immunotherapy GBR B 이세훈(성균관의대)
14:30~14:55 Uncovering determinants of immunotherapy response in advanced prostate cancer GBR B Aram Lyu(Fred Hutchinson Cancer Center, USA)
14:55~15:20 The "Viral-like" behavior of pancreatic cancer GBR B 유은애(고려대)
13:40~14:05 Current Lu-177 DOTATATE therapy for neuroendocrine tumor GBR C 김용일(울산의대)
14:05~14:30 Perspective of PSMA theranostics: Current clinical trial results and future direction GBR C 서훈녕(노바티스)
14:30~14:55 How to use dosimetry to predict personalized efficacy - current possibilities, limitations, and future directions GBR C 하승균(가톨릭의대)
14:55~15:20 Spatial omics-driven optimization of theranostic strategies in the tumor microenvironment GBR C 배성우(포트래이)
13:40~14:10 How to write a high-quality scientific manuscript according to the reporting guidelines Rose 허선(한림의대)
14:10~14:40 The ingredients of a truly great scientific publication: How to prepare for it, execute it, and build on it Rose Sue S. Yom(University of California San Francisco, USA)
14:40~15:10 Challenges in accepting manuscripts worthwhile to read and cite Rose 안용찬(노원을지병원)
15:40~16:05 Burden of lung cancer incidence attributable to particulate matter air pollution in South Korea GBR A 김선영(국립암센터 국제암대학원대학교)
16:05~16:30 Radiation exposure and cancer risk: An epidemiological perspective GBR A 이원진(고려의대)
16:30~16:55 Population attributable fraction of cancer associated with occupational exposure GBR A 김양우(한양대병원)
16:55~17:20 토론 GBR A
15:40~16:05 Enhanced CAR-T cell therapy using a novel gene modification GBR B 최경호(서울대)
16:05~16:30 Tumor microenvironment-modulating CAR-NK/T therapeutics GBR B 장미희(KIST)
16:30~16:55 Innovative mRNA platform for vaccine development GBR B 김윤기(KAIST)
16:55~17:20 Scientific basis of personalized cancer vaccine GBR B 백순명(테라젠바이오)
15:40~16:05 Evaluating targeted therapy for BRAF V600E-mutant RAI-refractory DTC: Insights from a Chinese cohort of the dabrafenib plus trametinib registry study GBR C Xiangqian Zheng(Tianjin Medical University Cancer Institute and Hospital, China)
16:05~16:30 Next-generation sequencing–guided nationwide umbrella trial for R/M HNSCC GBR C 김범석(서울의대)
16:30~16:55 The inheritance and the development of Chinese oral maxillofacial head neck oncology GBR C Chenping Zhang(Shanghai Jiao Tong University School of Medicine, China)
16:55~17:20 Neoadjuvant immunotherapy for resectable HNSCC: Clinical and translational insights GBR C 김창곤(연세의대)
15:40~16:05 Local ablative treatment in oligometastatic NSCLC: Benefits according to oligometastasis category and systemic modalities Rose 임채홍(고려의대)
16:05~16:30 Pulmonologist's perspective on diagnosis and management of oligometastasis from lung cancer Rose 이은혜(연세의대)
16:30~16:55 Oligometastasis in GI cancer: Numbers, biology, and surgical decision-making Rose Nobuhisa Matsuhashi(Gifu University Graduate School of Medicine, Japan)
16:55~17:20 Oligometastatic esophagogastric cancer (OMEC): Definition and treatment recommendations Rose Peter van Rossum(Amsterdam UMC, Netherlands)

Day 2 2026-06-26 (금) 59강

09:00~09:20 From LLMs to autonomous agents: The next paradigm shift in oncology GBR A 팽한솔(하해호)
09:20~09:40 Beyond R&D boundaries: Self-driving bio-innovation with collaborative generative AI multi-agents GBR A 이희은(BioNexus)
09:40~10:00 Next-generation clinical decision support: Multimodal AI agents as clinicians GBR A 손명희(삼성서울병원)
09:00~09:20 Myeloid reprogramming in cancer: TAMs, MDSCs, and immune modulation GBR B 김태진(성균관의대)
09:20~09:40 T cell dynamics in tumor immunity: Activation, exhaustion, and reprogramming GBR B 최일규(DGIST)
09:40~10:00 Evolving landscape of clinical cancer immunotherapy GBR B 최윤지(고려의대)
09:00~09:20 Epigenetic gene regulation in colon cancer GBR C 정인경(KAIST)
09:20~09:40 The biology of adherent-to-suspension transition in metastasis GBR C 박현우(연세대)
09:40~10:00 Targeting the NuRD chromatin remodeling complex as a therapeutic vulnerability in AML GBR C 이경민(한양대)
09:00~09:20 Beyond survival: Integrating treatment and life-course oncology for young women with breast cancer Rose 김희정(울산의대)
09:20~09:40 Young age colorectal cancer Rose 박은정(울산의대)
09:40~10:00 Young age gynecology cancer Rose 권병수(경희의대)
09:00~09:20 Functional genomics–driven mapping of signaling architectures and therapeutic vulnerabilities in lymphoma Carnation 최재우(연세의대)
09:20~09:40 Mesothelin Orchestrates an Immune-Restrained Tumor Microenvironment in SMAD4-Deficient PDAC Carnation 이수형(건국대 수의대)
09:40~10:00 Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells Carnation Hyuncheol Jung(University of California, San Francisco, USA)
10:20~11:00 Turning ideas into impact: Succeeding in investigator-initiated oncology trials GBR 안명주(한양의대)
11:00~11:40 Oncohistones: An ABC in 3D chromatin hijacking in cancer GBR Nada Jabado(McGill University, Canada)
12:10~12:50 Pembrolizumab in gastric cancer: Reimbursement-driven changes in clinical practice and evolving evidence GBR B 김진영(계명의대)
13:30~13:55 Integrative spatial multi-omics analysis for uncovering biological insight and treatment strategies GBR A 박종은(KAIST)
13:55~14:20 Multi-omics deconvolution–based tumor ecotype characterization for predicting prognosis and treatment response GBR A 빈진혁(연세의대)
14:20~14:45 Bridging single-cell OMICS and AI technology for cancer research GBR A 김종경(POSTECH)
14:45~15:10 AI virtual cell-based target and drug discovery GBR A 전민지(고려의대)
13:30~13:55 From postoperative ctDNA monitoring to adjuvant decision-making in colon cancer GBR B 김진원(서울의대)
13:55~14:20 Postoperative minimal residual disease detection using tumor-informed circulating tumor DNA analysis in gastric cancer GBR B 장대영(한림의대)
14:20~14:45 Extracellular Vesicle Proteome Analysis Improves Diagnosis of Recurrence in Triple-Negative Breast Cancer GBR B 정영호(충남대)
14:45~15:10 Integrating ctDNA MRD into perioperative oncology across solid cancers GBR B Eiji Oki(Graduate School of Medical Sciences, Kyushu University, Japan)
13:30~13:55 Integrative multiomics biomarker analysis for biliary tract cancer GBR C 유창훈(울산의대)
13:55~14:20 AI-driven characterization of hepatic fiber morphology to predict molecular alterations and future HCC risk in MASLD GBR C Hayato Nakagawa(Graduate School of Medicine, Mie University, Japan)
14:20~14:45 Precision strategy using clinically relevant molecular subtypes for biliary tract cancer GBR C 이성환(차의대)
14:45~15:10 Novel molecular and immunological stratification for therapeutic innovation in hepatocellular carcinoma GBR C Shinji Tanaka(Graduate School of Medicine, Institute of Science Tokyo, Japan)
13:30~14:00 Concurrent palliative care during systemic chemotherapy: Optimizing timing and referral Rose 이상헌(연세암병원)
14:00~14:30 Navigating treatment cessation in the era of immunotherapy and targeted agents: Challenges and strategies Rose 정은희(분당서울대병원)
14:30~15:00 Integration of oncology and palliative care: Evidence-based models and clinical outcomes Rose Egidio Del Fabbro(Augusta University, USA)
13:30~13:40 다학제 진료 도입의 역사 Carnation 서영진(가톨릭의대)
13:40~13:55 현행 다학제진료제도 및 급여지급 기준/내용에 관한 문제점 - 대한병리학회 Carnation 장기택(성균관의대)
13:55~14:10 현행 다학제진료제도 및 급여지급 기준/내용에 관한 문제점 - 대한방사선종양학회 Carnation 윤원섭(고려의대)
14:10~14:25 현행 다학제진료제도 및 급여지급 기준/내용에 관한 문제점 - 대한종양외과학회 Carnation 정상호(경상의대)
14:25~14:40 현행 다학제진료제도 및 급여지급 기준/내용에 관한 문제점 - 대한종양내과학회 Carnation 전홍재(차의대)
14:40~15:10 토론 Carnation
15:30~15:55 A multi-center experience of the Pediatric PRISSMM model to determine outcomes from real-world medical record data GBR A Neerav (Neal) Shukla(Memorial Sloan Kettering Cancer Center, USA)
15:55~16:20 Challenges and achievements of STREAM, a pediatric solid tumor precision medicine program of Korea GBR A 피지훈(서울의대)
16:20~16:45 Integrated genomic profiling, NGS-based MRD, and prospective multicenter trials in pediatric hematologic malignancies: The Korean Precision Medicine Initiative GBR A 김혜리(서울아산병원)
16:45~17:10 AACR Project GENIE: Powering precision medicine through real-world clinico-genomic data GBR A Shawn M. Sweeney(AACR PROJECT GENIE, USA)
15:30~15:55 Targeting HER2 with VRN101099, a covalent kinase inhibitor: Biology, selectivity, and clinical strategy GBR B 김성환(보로노이)
15:55~16:20 Precise ADC discovery along the bedside GBR B 남도현(성균관의대)
16:20~16:45 Next-generation ADCs: The promise of bispecific formats in overcoming clinical barriers GBR B 문성주(ABL Bio)
16:45~17:10 Bridging CDK7 biology and unmet medical needs in cancer treatment: Mocaciclib (Q901) as a novel treatment option for breast cancer GBR B 남기연(큐리언트)
15:30~15:55 Pathological insights into bladder cancer: Biomarkers for treatment response and resistance GBR C 조영미(울산의대)
15:55~16:20 Evolving role of antibody-drug conjugates in the management of advanced bladder cancer GBR C Yuji Miura(Toranomon Hospital, Japan)
16:20~16:45 Treatment strategies beyond EV + pembrolizumab in advanced urothelial carcinoma GBR C 박인근(서울아산병원)
16:45~17:10 The role of liquid biopsy for early detection and personalized treatment in bladder cancer GBR C Masaki Shiota(Kyushu University, Japan)
15:30~15:50 Medical evidence of antitumor agents with uncertain clinical benefit Rose 서재경(한국보건의료연구원)
15:50~16:10 Real world use of unproven antitumor therapies Rose 원영웅(한양의대)
16:10~16:30 Regulatory approval criteria for antitumor therapeutics Rose 박소라(식품의약품안전처)
16:30~17:10 토론 Rose
15:30~15:55 Targeting the ONECUT2-driven transcriptional network to reverse lineage transformation in neuroendocrine tumors Carnation Sungyong You(Cedars-Sinai Medical Center, USA)
15:55~16:20 Vascular reprogramming in liver metastasis and anti-angiogenic resistance Carnation Minah Kim(Columbia University, USA)
16:20~16:45 Insights into pancreatic cancer biology from spatially resolved profiling Carnation Jimin Min(New York University School of Medicine, USA)
16:45~17:10 Molecular profiling of fatal triple-M overlap syndrome: Deciphering myocarditis, myositis, and myasthenia gravis in ICI therapy Carnation Tae Gyu Oh(University of Oklahoma Medicine, USA)